

溫州康寧醫院股份有限公司
Wenzhou Kangning Hospital Co., Ltd.
Company incorporated in the People's Republic of China

enzhou Kangning Hospital Co., Ltd.

Company incorporated in the People's Republic of China

1443

3. $\frac{w}{w}$ $\frac{w}{w}$ A $\frac{w}{w}$ C

4. $\frac{w}{w}$ A $\frac{w}{w}$ C $\frac{w}{w}$ A $\frac{w}{w}$ C

$\frac{w}{w}$ A A

1. $\frac{w}{w}$ A $\frac{w}{w}$

B $\frac{w}{w}$ $\frac{w}{w}$ A $\frac{w}{w}$ A $\frac{w}{w}$ 28, 2022 $\frac{w}{w}$ B15,816,447. $\frac{w}{w}$ A $\frac{w}{w}$ C

$\frac{w}{w}$

() $\frac{w}{w}$ $\frac{w}{w}$ A $\frac{w}{w}$ C

() A $\frac{w}{w}$ $\frac{w}{w}$ $\frac{w}{w}$ C $\frac{w}{w}$ A $\frac{w}{w}$ C $\frac{w}{w}$

() $\frac{w}{w}$ A $\frac{w}{w}$ A A

(.) A          

(.) A          

2.     

                      

3.                       

                      

4.                       

                      

Major Limitations on the Review Scope of the Supplementary Report of the Independent Investigation

- (1) The scope of the review is limited to the period from the date of the first meeting of the Board of Directors to the date of the last meeting of the Board of Directors. The review does not cover the period before the first meeting of the Board of Directors or the period after the last meeting of the Board of Directors.
- (2) The scope of the review is limited to the period from the date of the first meeting of the Board of Directors to the date of the last meeting of the Board of Directors. The review does not cover the period before the first meeting of the Board of Directors or the period after the last meeting of the Board of Directors.

Opinions of the Independent Investigation Committee and the Board on the Supplementary Report of the Independent Investigation

The Independent Investigation Committee and the Board have reviewed the Supplementary Report of the Independent Investigation and have concluded that the report is accurate and reliable. The report provides a clear and concise summary of the findings of the investigation and the reasons for the findings. The report also provides a clear and concise summary of the recommendations of the investigation and the reasons for the recommendations. The report is a valuable tool for the Board and the Independent Investigation Committee in making decisions about the company's future.

25.16. -1.16. 8 / 16.3

Key Internal Control Issues	Rectifications
Entity-Level Review by COSO Framework	
Control Environment – Conflict of Interest Reporting Mechanism A conflict of interest reporting mechanism is a process that allows employees to report potential conflicts of interest that may arise in the course of their work. This mechanism is essential for maintaining the integrity of the organization and ensuring that all transactions are conducted in a fair and transparent manner. The mechanism typically involves a designated person or committee responsible for reviewing and resolving reported conflicts of interest. This person or committee should be independent of the reporting employee and should have the authority to take appropriate action to resolve the conflict. The mechanism should also include a process for monitoring and evaluating the effectiveness of the reporting mechanism and for making improvements as needed.	The conflict of interest reporting mechanism is a key component of the control environment. It is essential for ensuring that all transactions are conducted in a fair and transparent manner and for maintaining the integrity of the organization. The mechanism typically involves a designated person or committee responsible for reviewing and resolving reported conflicts of interest. This person or committee should be independent of the reporting employee and should have the authority to take appropriate action to resolve the conflict. The mechanism should also include a process for monitoring and evaluating the effectiveness of the reporting mechanism and for making improvements as needed.

Key Internal Control Issues	Rectifications
Entity-Level Review by COSO Framework	
Control Environment – Succession Plan The Board of Directors has approved a succession plan for the CEO and other key executives. The plan includes a process for identifying potential successors, evaluating their qualifications, and providing them with the necessary training and experience. The plan also includes a process for monitoring the progress of the succession process and making adjustments as needed.	The Board of Directors has approved a succession plan for the CEO and other key executives. The plan includes a process for identifying potential successors, evaluating their qualifications, and providing them with the necessary training and experience. The plan also includes a process for monitoring the progress of the succession process and making adjustments as needed.
Risk Assessments – Anti-Money Laundering Mechanism The company has implemented a risk assessment process for anti-money laundering (AML) that includes the following steps: - Identify the risks of AML in the company's operations. - Assess the likelihood and potential impact of each risk. - Develop and implement controls to mitigate the risks. - Monitor the effectiveness of the controls and make adjustments as needed.	The company has implemented a risk assessment process for anti-money laundering (AML) that includes the following steps: - Identify the risks of AML in the company's operations. - Assess the likelihood and potential impact of each risk. - Develop and implement controls to mitigate the risks. - Monitor the effectiveness of the controls and make adjustments as needed.

Key Internal Control Issues	Rectifications
Activity-level review	
Revenue and Accounts Receivable Management – Bad Debt Provision At the end of the year, the Accounts Receivable balance was \$1,200,000. The company's policy is to provide for bad debts at 60% of the Accounts Receivable balance. The provision for bad debts was \$720,000. The company's policy is to provide for bad debts at 100% of the Accounts Receivable balance. The provision for bad debts was \$1,200,000. The company's policy is to provide for bad debts at 100% of the Accounts Receivable balance. The provision for bad debts was \$1,200,000.	The company's policy is to provide for bad debts at 60% of the Accounts Receivable balance. The provision for bad debts was \$720,000. The company's policy is to provide for bad debts at 100% of the Accounts Receivable balance. The provision for bad debts was \$1,200,000. The company's policy is to provide for bad debts at 100% of the Accounts Receivable balance. The provision for bad debts was \$1,200,000.
Bank and Cash Management – Charitable Donation Management The company's policy is to provide for bad debts at 60% of the Accounts Receivable balance. The provision for bad debts was \$720,000. The company's policy is to provide for bad debts at 100% of the Accounts Receivable balance. The provision for bad debts was \$1,200,000. The company's policy is to provide for bad debts at 100% of the Accounts Receivable balance. The provision for bad debts was \$1,200,000.	The company's policy is to provide for bad debts at 60% of the Accounts Receivable balance. The provision for bad debts was \$720,000. The company's policy is to provide for bad debts at 100% of the Accounts Receivable balance. The provision for bad debts was \$1,200,000. The company's policy is to provide for bad debts at 100% of the Accounts Receivable balance. The provision for bad debts was \$1,200,000.

Key Internal Control Issues	Rectifications
Activity-level review	
	During the activity-level review, the Internal Control Adviser identified several issues related to the company's internal control system. The issues were categorized into three main areas: financial reporting, operational efficiency, and compliance with regulatory requirements. Financial Reporting: The Internal Control Adviser identified a weakness in the company's financial reporting process. Specifically, the company's accounting system did not adequately track and report on certain financial metrics, which could lead to inaccuracies in the financial statements. The Internal Control Adviser recommended that the company implement a new accounting system that would provide more accurate and timely financial reporting. Operational Efficiency: The Internal Control Adviser identified a weakness in the company's operational efficiency. Specifically, the company's internal control system did not adequately monitor and control the company's operational activities, which could lead to inefficiencies and waste. The Internal Control Adviser recommended that the company implement a new internal control system that would provide more effective monitoring and control of the company's operational activities. Compliance with Regulatory Requirements: The Internal Control Adviser identified a weakness in the company's compliance with regulatory requirements. Specifically, the company's internal control system did not adequately monitor and control the company's compliance with applicable laws and regulations, which could lead to non-compliance and potential legal consequences. The Internal Control Adviser recommended that the company implement a new internal control system that would provide more effective monitoring and control of the company's compliance with regulatory requirements.

Views of the Internal Control Adviser

The Internal Control Adviser's views on the company's internal control system are based on the results of the activity-level review. The Internal Control Adviser identified several weaknesses in the company's internal control system, which could lead to inaccuracies in the financial statements, inefficiencies and waste, and non-compliance with regulatory requirements. The Internal Control Adviser recommended that the company implement a new internal control system that would provide more accurate and timely financial reporting, more effective monitoring and control of the company's operational activities, and more effective monitoring and control of the company's compliance with regulatory requirements.

Views of the Audit Committee and the Board

The Audit Committee and the Board of Directors have reviewed the Internal Control Adviser's views on the company's internal control system. The Audit Committee and the Board of Directors have agreed to implement the Internal Control Adviser's recommendations to improve the company's internal control system. The Audit Committee and the Board of Directors have also agreed to monitor the company's progress in implementing the recommendations and to report on the results of the implementation to the shareholders.

B. The Company's Board of Directors has decided to suspend the trading of the Company's shares on the Shanghai Stock Exchange from January 11, 2022, to January 14, 2022. The Company's shares will resume trading on January 15, 2022. The Company's Board of Directors has decided to suspend the trading of the Company's shares on the Shanghai Stock Exchange from January 11, 2022, to January 14, 2022. The Company's shares will resume trading on January 15, 2022.

CONTINUED SUSPENSION OF TRADING

A. The Company's Board of Directors has decided to suspend the trading of the Company's shares on the Shanghai Stock Exchange from January 11, 2022, to January 14, 2022. The Company's shares will resume trading on January 15, 2022. The Company's Board of Directors has decided to suspend the trading of the Company's shares on the Shanghai Stock Exchange from January 11, 2022, to January 14, 2022. The Company's shares will resume trading on January 15, 2022.

Shareholders and potential investors of the Company are reminded to rationally deal with any information not officially released by the Company, and Shareholders and potential investors of the Company should exercise caution when dealing in the shares of the Company.

B. The Company's Board of Directors has decided to suspend the trading of the Company's shares on the Shanghai Stock Exchange from January 11, 2022, to January 14, 2022. The Company's shares will resume trading on January 15, 2022. The Company's Board of Directors has decided to suspend the trading of the Company's shares on the Shanghai Stock Exchange from January 11, 2022, to January 14, 2022. The Company's shares will resume trading on January 15, 2022.

Wenzhou Kangning Hospital Co., Ltd.
GUAN Weili
C. The Company's Board of Directors has decided to suspend the trading of the Company's shares on the Shanghai Stock Exchange from January 11, 2022, to January 14, 2022. The Company's shares will resume trading on January 15, 2022. The Company's Board of Directors has decided to suspend the trading of the Company's shares on the Shanghai Stock Exchange from January 11, 2022, to January 14, 2022. The Company's shares will resume trading on January 15, 2022.

A. The Company's Board of Directors has decided to suspend the trading of the Company's shares on the Shanghai Stock Exchange from January 11, 2022, to January 14, 2022. The Company's shares will resume trading on January 15, 2022. The Company's Board of Directors has decided to suspend the trading of the Company's shares on the Shanghai Stock Exchange from January 11, 2022, to January 14, 2022. The Company's shares will resume trading on January 15, 2022.

A. The Company's Board of Directors has decided to suspend the trading of the Company's shares on the Shanghai Stock Exchange from January 11, 2022, to January 14, 2022. The Company's shares will resume trading on January 15, 2022. The Company's Board of Directors has decided to suspend the trading of the Company's shares on the Shanghai Stock Exchange from January 11, 2022, to January 14, 2022. The Company's shares will resume trading on January 15, 2022.